Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dawnrays Pharmaceutical Holdings Ltd. (HK:2348)
:2348
Holding HK:2348?
Track your performance easily
2348 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$1.03 - HK$1.40
Previous CloseN/A
Volume344.00K
Average Volume (3M)189.47K
Market Cap
HK$1.80B
Enterprise ValueHK$696.07M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)3.0
Beta0.23
Next Earnings
Mar 21, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield6.67%
Share Statistics
EPS (TTM)0.41
Shares Outstanding1,501,893,000
10 Day Avg. Volume165,600
30 Day Avg. Volume189,467
Standard Deviation0.09
R-Squared0.12
Alpha0.00793
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Dawnrays Pharmaceutical Holdings Ltd. News
PremiumCompany Announcements
Dawnrays Pharma Changes Hong Kong Share Registrar
PremiumCompany Announcements
Dawnrays Pharmaceutical Incentivizes Staff with Share Options
PremiumCompany Announcements
Dawnrays Pharmaceutical Appoints New CEO
PremiumCompany Announcements
Dawnrays Pharmaceutical Announces CEO Resignation
PremiumCompany Announcements
Dawnrays Pharmaceutical Declares Interim Dividend
PremiumCompany Announcements
Dawnrays Pharmaceutical Posts Remarkable Profit Growth
PremiumCompany Announcements
Dawnrays Pharmaceutical Prepares for Financial ReviewOptions Prices
Currently, No data available
---
Ownership Overview
―
Insiders
5.13%
Mutual Funds
― Other Institutional Investors
94.87% Public Companies and
Individual Investors
2348 FAQ
What was Dawnrays Pharmaceutical Holdings Ltd.’s price range in the past 12 months?
Dawnrays Pharmaceutical Holdings Ltd. lowest stock price was HK$1.03 and its highest was HK$1.40 in the past 12 months.
What is Dawnrays Pharmaceutical Holdings Ltd.’s market cap?
Dawnrays Pharmaceutical Holdings Ltd.’s market cap is HK$1.80B.
When is Dawnrays Pharmaceutical Holdings Ltd.’s upcoming earnings report date?
Dawnrays Pharmaceutical Holdings Ltd.’s upcoming earnings report date is Mar 21, 2025 which is in 60 days.
How were Dawnrays Pharmaceutical Holdings Ltd.’s earnings last quarter?
Currently, no data Available
Is Dawnrays Pharmaceutical Holdings Ltd. overvalued?
According to Wall Street analysts Dawnrays Pharmaceutical Holdings Ltd.’s price is currently Overvalued.
Does Dawnrays Pharmaceutical Holdings Ltd. pay dividends?
Dawnrays Pharmaceutical Holdings Ltd. pays a N/A dividend of HK$0.078 which represents an annual dividend yield of 6.67%. See more information on Dawnrays Pharmaceutical Holdings Ltd. dividends here
What is Dawnrays Pharmaceutical Holdings Ltd.’s EPS estimate?
Dawnrays Pharmaceutical Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dawnrays Pharmaceutical Holdings Ltd. have?
Dawnrays Pharmaceutical Holdings Ltd. has 1,501,893,000 shares outstanding.
What happened to Dawnrays Pharmaceutical Holdings Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Dawnrays Pharmaceutical Holdings Ltd.?
Currently, no hedge funds are holding shares in HK:2348
---
Dawnrays Pharmaceutical Holdings Ltd. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.21%
12-Months-Change
Fundamentals
Return on Equity
18.65%
Trailing 12-Months
Asset Growth
13.24%
Trailing 12-Months
Company Description
Dawnrays Pharmaceutical Holdings Ltd.
Dawnrays Pharmaceutical (Holdings) Ltd is a major drug manufacturing company. The company operates two segments, including Intermediates and Bulk Medicines, and Finished Drugs. Most of its revenue is derived from the Finished Drugs segment. Nearly all of the company's sales are generated in Mainland China. It utilizes strategic partnerships as a component of its international strategies. The company is open to exploring potential acquisitions as a component of its overall growth strategy.
---
Technical Analysis
China Isotope & Radiation Corp.
―
China Lesso Group Holdings
―
Roiserv Lifestyle Services Co. Ltd. Class H
―
---